Sangamo Therapeutics (SGMOQ) Revenue (2010 - 2025)

Sangamo Therapeutics has reported Revenue for 16 years, with the latest figure at $14.2 million in Q4 2025.

• On a quarterly basis, Revenue rose 118.89% year-over-year to $14.2 million in Q4 2025; TTM through Dec 2025 was $39.6 million, a 30.3% decrease from a year earlier, with the FY2025 full-year figure at $39.6 million, down 31.57% from the prior year.
• Revenue was $14.2 million for Q4 2025 at Sangamo Therapeutics, up from $581000.0 in the prior quarter.
• The five-year high for Revenue was $158.0 million in Q1 2023, with the low at $356000.0 in Q2 2024.
• Average Revenue over 5 years is $24.7 million, with a median of $22.3 million recorded in 2021.
• The sharpest annual moves came in 2024 and 2025: Revenue tumbled 99.7% in 2024, then jumped 5042.13% in 2025.
• Over 5 years, Revenue stood at $28.0 million in 2021, then fell by 2.7% to $27.2 million in 2022, then slumped by 92.5% to $2.0 million in 2023, then soared by 218.32% to $6.5 million in 2024, then jumped by 118.89% to $14.2 million in 2025.
• The last three Revenue figures came in at $14.2 million (Q4 2025), $581000.0 (Q3 2025), and $18.3 million (Q2 2025), per Business Quant data.